Healthcare -
Biotechnology - NASDAQ - US
$ 0.1019
-6.34 %
$ 5.86 M
Market Cap
0.0
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart CNSP
FINANCIALS
Balance Sheet
CNS Pharmaceuticals, Inc.
| Current Assets | 1.59 M |
| Cash & Short-Term Investments | 549 K |
| Receivables | 0 |
| Other Current Assets | 1.04 M |
| Non-Current Assets | 110 K |
| Long-Term Investments | 0 |
| PP&E | 4.93 K |
| Other Non-Current Assets | 105 K |
| Current Liabilities | 6.13 M |
| Accounts Payable | 5.83 M |
| Short-Term Debt | 301 K |
| Other Current Liabilities | 0 |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
CNS Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 4.13 K |
| Gross Profit | -4.13 K |
| Operating Expenses | 18.9 M |
| Operating Income | -18.9 M |
| Other Expenses | -13.9 K |
| Net Income | -18.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CNS Pharmaceuticals, Inc.
| Net Income | -18.9 M |
| Depreciation & Amortization | 4.13 K |
| Capital Expenditures | -3.9 K |
| Stock-Based Compensation | 1.01 M |
| Change in Working Capital | 3.7 M |
| Others | 2.38 M |
| Free Cash Flow | -14.1 M |
Wall Street Analysts Price Targets
CNS Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for CNSP of $0.5 , with forecasts ranging from
a
low of
$0.5 to a high of $0.5 .
CNSP Lowest Price Target
Wall Street Target
0.5 USD
390.68%
CNSP Average Price Target
Wall Street Target
0.5 USD
390.68%
CNSP Highest Price Target
Wall Street Target
0.5 USD
390.68%
4. DIVIDEND
ANALYSIS
CNSP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CNS Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
90 K USD 4
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
11 months ago
Feb 01, 2024
|
Bought
10 K USD
|
Gumulka Jerzy
Director
|
+ 33333
|
0.3 USD |
|
11 months ago
Feb 01, 2024
|
Bought
10 K USD
|
Evans Carl Anthony
Director
|
+ 33333
|
0.3 USD |
|
11 months ago
Feb 01, 2024
|
Bought
20 K USD
|
Downs Christopher
Chief Financial Officer
|
+ 66666
|
0.3 USD |
|
11 months ago
Feb 01, 2024
|
Bought
50 K USD
|
Climaco John M
Chief Executive Officer
|
+ 166666
|
0.3 USD |
|
1 year ago
Aug 22, 2023
|
Bought
34.2 K USD
|
Downs Christopher
Chief Financial Officer
|
+ 27000
|
1.2658 USD |
|
1 year ago
Aug 16, 2023
|
Bought
4.94 K USD
|
Climaco John M
Chief Executive Officer
|
+ 2750
|
1.798 USD |
|
2 years ago
Dec 06, 2022
|
Sell 13.6 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5500
|
2.47 USD |
|
2 years ago
Dec 07, 2022
|
Sell 13.5 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5500
|
2.46 USD |
|
2 years ago
Dec 08, 2022
|
Sell 13.2 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5500
|
2.4 USD |
|
2 years ago
Dec 09, 2022
|
Sell 6.8 K
USD
|
Priebe Waldemar
10 percent owner
|
- 2798
|
2.43 USD |
|
1 year ago
Mar 10, 2023
|
Sell 6.45 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.29 USD |
|
1 year ago
Mar 13, 2023
|
Sell 6.5 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.3 USD |
|
1 year ago
Mar 14, 2023
|
Sell 6.75 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.35 USD |
|
1 year ago
Mar 15, 2023
|
Sell 6.1 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.22 USD |
|
1 year ago
Mar 16, 2023
|
Sell 6.2 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.24 USD |
|
1 year ago
Mar 17, 2023
|
Sell 5.65 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.13 USD |
|
1 year ago
Mar 20, 2023
|
Sell 5.4 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.08 USD |
|
1 year ago
Mar 21, 2023
|
Sell 5.5 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.1 USD |
|
1 year ago
Mar 22, 2023
|
Sell 5.4 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.08 USD |
|
1 year ago
Mar 23, 2023
|
Sell 10.8 K
USD
|
Priebe Waldemar
10 percent owner
|
- 10000
|
1.08 USD |
|
1 year ago
Mar 24, 2023
|
Sell 5.4 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.08 USD |
|
1 year ago
Mar 27, 2023
|
Sell 5.45 K
USD
|
Priebe Waldemar
10 percent owner
|
- 5000
|
1.09 USD |
|
1 year ago
Mar 28, 2023
|
Sell 10.4 K
USD
|
Priebe Waldemar
10 percent owner
|
- 10000
|
1.04 USD |
|
1 year ago
Apr 19, 2023
|
Bought
4.25 K USD
|
Gumulka Jerzy
Director
|
+ 2500
|
1.7 USD |
|
1 year ago
Apr 17, 2023
|
Bought
9.92 K USD
|
Downs Christopher
Chief Financial Officer
|
+ 3100
|
3.2 USD |
|
1 year ago
Apr 10, 2023
|
Bought
5.31 K USD
|
Gumulka Jerzy
Director
|
+ 7173
|
0.74 USD |
|
1 year ago
Apr 12, 2023
|
Bought
10.4 K USD
|
Climaco John M
Chief Executive Officer
|
+ 15000
|
0.6939 USD |
|
3 years ago
Dec 06, 2021
|
Bought
4.7 K USD
|
Downs Christopher
Chief Financial Officer
|
+ 5000
|
0.9403 USD |
|
3 years ago
Nov 19, 2021
|
Bought
5.19 K USD
|
Downs Christopher
Chief Financial Officer
|
+ 4500
|
1.1537 USD |
|
4 years ago
Aug 24, 2020
|
Bought
290 K USD
|
Downs Christopher
Chief Financial Officer
|
+ 142000
|
2.04 USD |
7. News
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof.
accesswire.com
- 1 month ago
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population.
accesswire.com
- 1 month ago
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
accesswire.com
- 2 months ago
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM study Quarter marked by pipeline expansion with in-license of TPI 287, a late stage novel potential blood brain barrier permeable abeotaxane for treatment of brain malignancies HOUSTON, TX / ACCESSWIRE / November 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter 2024 ended September 30, 2024. "Our team has made nothing short of transformational advancements throughout 2024.
accesswire.com
- 2 months ago
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.
accesswire.com
- 2 months ago
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
accesswire.com
- 2 months ago
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock (or common stock equivalents in lieu thereof) pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share. The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction of customary closing conditions.
accesswire.com
- 2 months ago
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. The segment can be accessed here.
accesswire.com
- 3 months ago
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 16,2024 at 4:00 PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.
accesswire.com
- 3 months ago
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
accesswire.com
- 3 months ago
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on September 10, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the equity requirement under Nasdaq's Listing Rule 5550(b)(1), subject to Nasdaq Mandatory Panel Monitor related to the equity requirement for a period of one year. Now that the Company has regained compliance with Listing Rule 5550(b)(1), Nasdaq has advised the Company that this matter is now closed.
accesswire.com
- 4 months ago
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
accesswire.com
- 4 months ago
8. Profile
Summary
CNS Pharmaceuticals, Inc. CNSP
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 5.86 M
Dividend Yield
0.00%
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Contact
2100 West Loop South, Houston, TX, 77027
https://www.cnspharma.com
IPO
Date
Nov. 8, 2019
Employees
3
Officers
Mr. Christopher S. Downs CPA, CTP, FP&A
Chief Financial Officer
Mr. John Michael Climaco Esq., J.D.
Chief Executive Officer, President & Director
Dr. Sandra L. Silberman M.D., Ph.D.
Chief Medical Officer
Dr. Donald H. Picker Ph.D.
Chief Science Officer
Dr. Waldemar Priebe Ph.D.
Founder